Market Place
Sourcing Support
Galapagos Presents Cancer Cell Therapy Innovation at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Galapagos Reports Q3 2024 Financial Results & Business Update
30 Oct 2024 //
GLOBENEWSWIRE
Galapagos Welcomes Oleg Nodelman To Board Of Directors
07 Oct 2024 //
GLOBENEWSWIRE
Excellos to Support Galapagos’ CAR-T Cell Therapy Clinical Study
01 Oct 2024 //
CONTRACT PHARMA
Galapagos receives transparency notification from EcoR1 Capital
30 Sep 2024 //
GLOBENEWSWIRE
Galapagos receives transparency notification from EcoR1 Capital
16 Sep 2024 //
GLOBENEWSWIRE
Galapagos receives transparency notification from FMR LLC
03 Sep 2024 //
GLOBENEWSWIRE
Galapagos Investor Signals Intent To Influence Undervalued Company
26 Aug 2024 //
FIERCE BIOTECH
Galapagos Gets FDA Clearance For Phase 1/2 CAR-T Study In Lymphoma
23 Aug 2024 //
GLOBENEWSWIRE
Galapagos receives transparency notification from FMR LLC
20 Aug 2024 //
GLOBENEWSWIRE
Galapagos pauses CAR-T cell therapy trial over Parkinsonism case
03 Aug 2024 //
FIERCE BIOTECH
Galapagos Reports H1 2024 Results And Q2 Business Update
01 Aug 2024 //
GLOBENEWSWIRE
BridGene And Galapagos Expand Collaboration On SMARCA2 PROTAC
01 Aug 2024 //
PR NEWSWIRE
Galapagos Presents GLPG5101 NHL Data At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Erasca restructures; Novartis moves to complete MorphoSys deal
17 May 2024 //
BIOPHARMADIVE
Galapagos creates new subscription right plans
16 May 2024 //
GLOBENEWSWIRE
Galapagos bolsters decentralized CAR-T manufacturing
16 May 2024 //
GLOBENEWSWIRE
Galapagos, Blood Centers Collaborate On Decentralized US CAR-T Manufacturing
15 May 2024 //
GLOBENEWSWIRE
Galapagos reports first quarter 2024 financial results
02 May 2024 //
GLOBENEWSWIRE
Galapagos™ Shareholders Adopt Board`s Resolutions At Meetings
30 Apr 2024 //
GLOBENEWSWIRE
Galapagos Shows Innovative Approach in Hematological Cancer Data at EBMT
04 Apr 2024 //
GLOBENEWSWIRE
Galapagos Publishes 2023 Annual Report and Announces Annual Meetings
28 Mar 2024 //
GLOBENEWSWIRE
Galapagos appoints Dickinson as Non-Executive independent Director to its Board
26 Mar 2024 //
GLOBENEWSWIRE
Galapagos halts lupus CAR-T work, confirms 100 layoffs this year
24 Feb 2024 //
FIERCE BIOTECH
Galapagos announces full year 2023 results and outlook for 2024
22 Feb 2024 //
GLOBENEWSWIRE
Galapagos presents at EBMT-EHA annual meeting 2024
15 Feb 2024 //
GLOBENEWSWIRE
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
31 Jan 2024 //
GLOBENEWSWIRE
Galapagos enters into collaboration agreement with Thermo Fisher Scientific
04 Jan 2024 //
GLOBENEWSWIRE
Galapagos Collaborates With BridGene Biosciences To Develop Cancer Treatments
04 Jan 2024 //
YAHOO FINANCE
BridGene Biosciences Announces Strategic Collaboration with Galapagos
03 Jan 2024 //
PR NEWSWIRE
Galapagos establishes strategic collaboration with BridGene Biosciences
03 Jan 2024 //
GLOBENEWSWIRE
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
02 Jan 2024 //
GLOBENEWSWIRE
Galapagos announces start of PAPILIO-1 Ph 1/2 multiple myeloma study of GLPG5301
19 Dec 2023 //
GLOBENEWSWIRE
Galapagos presents new encouraging data at ASH 2023 from GLPG5201 and GLPG5101
09 Dec 2023 //
GLOBENEWSWIRE
Galapagos to Host KOL Event on December 10, 2023
07 Dec 2023 //
GLOBENEWSWIRE
Landmark Bio Signs Agreement to Manufacture Galapagos` Oncology Programs
06 Nov 2023 //
PR NEWSWIRE
Galapagos reports third quarter 2023 results
02 Nov 2023 //
GLOBENEWSWIRE
Galapagos signs letter of intent to transfer Jyseleca® business
30 Oct 2023 //
GLOBENEWSWIRE
Galapagos appoints Simon Sturge to its Board of Directors
19 Sep 2023 //
GLOBENEWSWIRE
Galapagos slashes Jyseleca sales projection, scraps submissions
04 Aug 2023 //
FIERCE PHARMA
Galapagos announces first half-year 2023 financial results
03 Aug 2023 //
GLOBENEWSWIRE
Galapagos appoints Thad Huston as CFO and Chief Operating Officer
15 Jun 2023 //
GLOBENEWSWIRE
Galapagos appoints Dr. Susanne Schaffert as independent Director
12 Jun 2023 //
GLOBENEWSWIRE
Galapagos to showcase CAR-T point-of-care manufacturing and Phase 1/2 CLL data
05 Jun 2023 //
GLOBENEWSWIRE
Galapagos announces start of Phase 2 study with TYK2 inhibitor, GLPG3667
23 May 2023 //
GLOBENEWSWIRE
Galapagos demonstrates commitment to immunology with new data at EULAR
22 May 2023 //
GLOBENEWSWIRE
Galapagos creates new subscription right plans
05 May 2023 //
GLOBENEWSWIRE
Maria Fardis ends a two-year CEO hiatus; More leadership turnover at Galapagos
05 May 2023 //
ENDPTS
Galapagos announces first quarter 2023 financial results
04 May 2023 //
GLOBENEWSWIRE
Galapagos announces departure of Bart Filius, Chief Operating Officer and CFO
02 May 2023 //
GLOBENEWSWIRE
Galapagos initiates Phase 3 program with filgotinib in patients with AAS
26 Apr 2023 //
GLOBENEWSWIRE
Galapagos shareholders approve all resolutions proposed by the BOD
25 Apr 2023 //
GLOBENEWSWIRE
Galapagos, following Sanofi’s playbook, offloads R&D site to CRO
31 Mar 2023 //
FIERCE BIOTECH
Galapagos and NovAliX enter into an integrated drug discovery collaboration
30 Mar 2023 //
GLOBENEWSWIRE
Galapagos publishes 2022 annual report and announces Annual Shareholders Meeting
23 Mar 2023 //
GLOBENEWSWIRE
Galapagos increases share capital through subscription right exercises
20 Mar 2023 //
GLOBENEWSWIRE
Galapagos to present new data from long-term extension study of filgotinib
27 Feb 2023 //
GLOBENEWSWIRE
Galapagos goes 0-for-3 on inflammation program as it cuts early-stage candidate
24 Feb 2023 //
ENDPTS
Galapagos announces full year 2022 results and outlook for 2023
23 Feb 2023 //
GLOBENEWSWIRE
Galapagos presented efficacy data for CAR-T candidate, GLPG5201, in rrCLL
09 Feb 2023 //
GLOBENEWSWIRE
